Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo)
| العنوان: | Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo) |
|---|---|
| المؤلفون: | Loes M. Pronk, Georgina V. Long, Alexander M. Menzies, Maria Gonzales, Alexander C.J. van Akkooi, Christian U. Blank, Johan Hansson, James Larkin, Elisa A. Rozeman, Christoph Hoeller, Myles Smith, Richard A. Scolyer |
| المصدر: | Journal of Clinical Oncology. 36:TPS9606-TPS9606 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Phases of clinical research, Ipilimumab, Neo adjuvant, Immune checkpoint, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Toxicity, medicine, Progression-free survival, Nivolumab, business, Adjuvant, medicine.drug |
| الوصف: | TPS9606Background: The outcome of high risk stage III melanoma patients (pts) is poor, with a 5 year overall survival (OS) rate of < 50%. Adjuvant (adj) high dose IPI significantly improves 5 year progression free survival (PFS) and OS and adj NIVO improves the median PFS even more. In stage IV pts, the combination of IPI and NIVO improves response rates (RR) and PFS compared to monotherapy, but at cost of higher toxicity. Neo-adjuvant (neoadj) treatment may be a favorable approach as immune checkpoint inhibition (ICI) is of greatest value at the moment of TCR triggering and therefore dependent on the amount of antigen. The phase Ib OpACIN study compared neoadj versus adj IPI plus NIVO. The pathological RR (pRR) was 80% in the neoadj arm, and to date after a median follow-up of 24 months, none of the responders has relapsed, while 4/10 pts have relapsed in the adj arm. Moreover, pts in the neoadj arm expanded more tumor-resident TCR clones than adj treated pts. Neoadj IPI+NIVO was feasible, but toxicity w... |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::6df73345d5eca811834c1e72d839158bTest https://doi.org/10.1200/jco.2018.36.15_suppl.tps9606Test |
| رقم الانضمام: | edsair.doi...........6df73345d5eca811834c1e72d839158b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|